VHIO to incorporate Guardant Health’s breakthrough liquid biopsy technology in 2021
During 2021, the Vall d’Hebron Institute of [...]
A step forward in the validation of reliable preclinical models for cancer research
*Source: EurOPDX Consortium Barcelona, January 8, [...]
Seeking out predictive biomarkers for a longer-term response to immunotherapy against NSCLC
While the rapidly emerging arsenal of immune-based [...]
The promise of KEYNOTE-177: Nature Reviews Clinical Oncology’s Research Highlight with invited comment from Josep Tabernero
As a leading cause of cancer death [...]
Vall d’Hebron researchers publish a review on the influence of radiotherapy and cancer surgery on the immune system
The work, published in Frontiers in Oncology, [...]
Peptomyc announces new equity financing round led by Aurora Science
Peptomyc S.L., a spin-off from VHIO – [...]
The multicentre exchange and multidisciplinary data analysis improves the clinical classification of the genetic variants that predispose to cancer
This may be gathered from the results [...]
Under a Cancer Cell Spotlight: unleashing the promise of KRAS targeting therapy
Published today in Cancer Cell* as a [...]
RAPIDO study shows promise for the optimal treatment of high-risk locally advanced rectal cancer
Results from the RAPIDO phase III multicenter, [...]
VHIO’s Ana Oaknin elected as co-Chair of the Gynecologic Cancer InterGroup’s Cervix Cancer Committee
News just in, Principal Investigator of our [...]